Public health actions to control new SARS-CoV-2 variants

Nathan D Grubaugh; Emma B Hodcroft; Joseph R Fauver; Alexandra L Phelan; Muge Cevik

doi:10.1016/j.cell.2021.01.044

Public health actions to control new SARS-CoV-2 variants

Cell. 2021 Mar 4;184(5):1127-1132. doi: 10.1016/j.cell.2021.01.044. Epub 2021 Jan 29.

Authors

Nathan D Grubaugh¹, Emma B Hodcroft², Joseph R Fauver³, Alexandra L Phelan⁴, Muge Cevik⁵

Affiliations

¹ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA; Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT, USA; Yale Institute for Global Health, Yale University, New Haven, CT, USA.
² Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Electronic address: emma.hodcroft@ispm.unibe.ch.
³ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA. Electronic address: josephfauver@yale.edu.
⁴ Center for Global Health Science and Security, Georgetown University, Washington, DC, USA; O'Neill Institute for National and Global Health Law, Georgetown University Law Center, Washington, DC, USA. Electronic address: alexandra.phelan@georgetown.edu.
⁵ Division of Infection and Global Health Research, School of Medicine, University of St Andrews, Fife, UK.

Abstract

Recent reports suggest that some SARS-CoV-2 genetic variants, such as B.1.1.7, might be more transmissible and are quickly spreading around the world. As the emergence of more transmissible variants could exacerbate the pandemic, we provide public health guidance for increased surveillance and measures to reduce community transmission.

MeSH terms

Age Factors
COVID-19 / epidemiology
COVID-19 / prevention & control*
COVID-19 / transmission*
COVID-19 / virology
Communicable Disease Control*
Epidemiological Monitoring
Global Health
Humans
Mandatory Programs
Pandemics
SARS-CoV-2 / genetics*
SARS-CoV-2 / physiology
Travel / legislation & jurisprudence
United Kingdom / epidemiology
Vulnerable Populations

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States